Histogranin-Like Antinociceptive and Anti-Inflammatory Derivatives of o-Phenylenediamine and Benzimidazole

Histogranin (HN)-like nonpeptides were designed and synthesized using benzimidazole (compound 1) and o-phenylenediamine (compounds 2–7) as scaffolds for the attachment of phenolic hydroxyl and basic guanidino pharmacophoric elements present in HN. The benzimidazole derivative N-5-guanidinopentanamide-(2R)-yl-2-(p-hydroxybenzyl)-5-carboxybenzimidazole (1) and the o-phenylenediamine derivative N-5-guanidinopentanamide-(2S)-yl-2-N-(p-hydroxyphenylacetyl) phenylenediamine (2) were more potent analgesics than HN in both the mouse writhing (5.5 and 3.5 as potent as HN, respectively) and tail-flick (11.8 and 8.0 as potent as HN, respectively) pain assays. Improvements in the potencies and times of action of compound 2 in the mouse writhing test were obtained by attaching carboxyl (6)or p-Cl-benzoyl (7) groups at position 4 of the (2R) o-phenylenediamine derivative (5). In rats, compounds 2 (80 nmol i.t.), 6 (36 nmol i.t.), and 7 (18 nmol i.t.) were effective in blocking both persistent inflammatory pain in the formalin test and hyperalgesia in the complete Freund adjuvant assay. Compounds 2, 6, and 7, but not compound 1 at 10 nmol (i.c.v.) also mimicked the HN (60 nmol i.c.v.) blockade of N-methyl-d-aspartate (NMDA)-induced convulsions in mice. Finally, in primary cultures of rat alveolar macrophages, HN and compounds 1, 2, 6, and 7 (10-8 M) significantly blocked lipopolysaccharide-induced cyclooxygenase-2 induction and prostaglandin E2 secretion. These studies indicate that both derivatives of benzimidazole and o-phenylenediamine mimic the in vivo antinociceptive and in vitro anti-inflammatory effects of HN, but the HN protection of mice against NMDA-induced convulsions is mimicked only by the o-phenylenediamine derivatives.

[1]  Yu-ping Jia,et al.  Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation , 2003, Pain.

[2]  I. Lemaire,et al.  Bioactive peptidic analogues and cyclostereoisomers of the minimal antinociceptive histogranin fragment-(7-10). , 2003, Journal of Medicinal Chemistry.

[3]  Lu-Yuan Lee,et al.  Activation of dopamine D2-like receptors attenuates pulmonary C-fiber hypersensitivity in rats. , 2003, American journal of respiratory and critical care medicine.

[4]  T. Hermann,et al.  Solid-phase synthesis of benzimidazole libraries biased for RNA targets , 2003 .

[5]  G. P. Bean.  An AM1 study of the effect of substituents on the bond dissociation energies of anilines, phenols, and α-substituted toluenes , 2002 .

[6]  S. Salvadori,et al.  Potent δ-Opioid Receptor Agonists Containing the Dmt−Tic Pharmacophore , 2002 .

[7]  A. Fischman,et al.  Novel (bisarylmethoxy)butylpiperidine analogues as neurotransmitter transporter inhibitors with activity at dopamine receptor sites. , 2002, Bioorganic & medicinal chemistry.

[8]  S. Bräse,et al.  The recent impact of solid-phase synthesis on medicinally relevant benzoannelated nitrogen heterocycles. , 2002, Bioorganic & medicinal chemistry.

[9]  K. Fukase,et al.  New efficient route for solid-phase synthesis of benzimidazole derivatives. , 2002, Journal of combinatorial chemistry.

[10]  N. Calcutt,et al.  Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. , 2002, Diabetes.

[11]  H. Heitsch.  Non-peptide antagonists and agonists of the bradykinin B(2) receptor. , 2002, Current Medicinal Chemistry.

[12]  A. Hama,et al.  Selective antihyperalgesic effect of [Ser1] histogranin on complete Freund's adjuvant-induced hyperalgesia in rats , 2002, Pain.

[13]  S. Salvadori,et al.  Potent delta-opioid receptor agonists containing the Dmt-Tic pharmacophore. , 2002, Journal of Medicinal Chemistry.

[14]  N. Ede,et al.  Solid-phase synthesis of quinoxalines on SynPhase™ Lanterns , 2001 .

[15]  P. Isakson,et al.  The Acute Antihyperalgesic Action of Nonsteroidal, Anti-Inflammatory Drugs and Release of Spinal Prostaglandin E2 Is Mediated by the Inhibition of Constitutive Spinal Cyclooxygenase-2 (COX-2) but not COX-1 , 2001, The Journal of Neuroscience.

[16]  K. Franklin,et al.  Characterization of the analgesic properties of nomifensine in rats , 2001, Pharmacology Biochemistry and Behavior.

[17]  V. Hruby.  Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind--body problem. , 2001, Accounts of chemical research.

[18]  S. Lemaire,et al.  Interactions of histogranin and related peptides with dopamine D2 receptor in rat brain membranes , 2001, Synapse.

[19]  J. W. Leem,et al.  The role of peripheral N-methyl-D-aspartate receptors in Freund's complete adjuvant induced mechanical hyperalgesia in rats. , 2000, Neuroscience Letters.

[20]  S. Lemaire,et al.  Non-opioid antinociceptive effects of supraspinal histogranin and related peptides: possible involvement of central dopamine D2 receptor , 2000, Pharmacology Biochemistry and Behavior.

[21]  R. Johns,et al.  Activation of cGMP-dependent protein kinase Ialpha is required for N-methyl-D-aspartate- or nitric oxide-produced spinal thermal hyperalgesia. , 2000, European journal of pharmacology.

[22]  J. Bikker,et al.  Design and biological evaluation of non-peptide analogues of omega-conotoxin MVIIA. , 2000, Bioorganic & medicinal chemistry letters.

[23]  M. Schwarz,et al.  Solid-phase synthesis of substituted benzimidazoles , 1999 .

[24]  J. Gard,et al.  Necklace-Coded Polymer-Supported Combinatorial Synthesis of 2-Arylaminobenzimidazoles , 1999 .

[25]  P. Hipskind,et al.  Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists. , 1999, Bioorganic & medicinal chemistry letters.

[26]  A. Hama,et al.  NMDA-induced spinal hypersensitivity is reduced by naturally derived peptide analog [Ser1]histogranin. , 1999, Pharmacology, biochemistry, and behavior.

[27]  V. Hruby,et al.  De Novo Design, Synthesis, and Biological Activities of High-Affinity and Selective Non-Peptide Agonists of the δ-Opioid Receptor‖ , 1998 .

[28]  J. Bikker,et al.  Synthesis of a non-peptide analogue of omega-conotoxin MVIIA , 1998 .

[29]  W. DeGrado,et al.  Solid-Phase Synthesis of Benzopiperazinones , 1998 .

[30]  R. Rivero,et al.  SOLID PHASE SYNTHESIS OF 3,4-DISUBSTITUTED-7-CARBAMOYL-1,2,3,4-TETRAHYDROQUINOXALIN-2-ONES , 1997 .

[31]  A. Hama,et al.  Suppression of neuropathic pain by a naturally-derived peptide with NMDA antagonist activity , 1997, Brain Research.

[32]  T. Vanderah,et al.  Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal or nerve-injured rats , 1997, Pain.

[33]  J. Sagen,et al.  A natural peptide with NMDA inhibitory activity reduces tonic pain in the formalin model , 1997, Neuroreport.

[34]  R. Whelpton,et al.  Evidence for modulatory effects of substance P fragments (1–4) and (8–11) on endogenous dopamine outflow in rat striatal slices , 1996, Neuroscience Letters.

[35]  V. Shukla,et al.  Histogranin, a modified histone H4 fragment endowed with N-methyl-D-aspartate antagonist and immunostimulatory activities. , 1995, Life sciences.

[36]  V. Shukla,et al.  Synthesis and biological activity of histogranin and related peptides. , 1995, Canadian journal of physiology and pharmacology.

[37]  V. Shukla,et al.  N-methyl-D-aspartate receptor antagonist activity and phencyclidine-like behavioral effects of the pentadecapeptide, [Ser1]histogranin , 1995, Pharmacology Biochemistry and Behavior.

[38]  Y. Yoshimura,et al.  Nonpeptide Angiotensin II Receptor Antagonists. Synthesis and Biological Activity of Potential Prodrugs of Benzimidazole‐7‐ carboxylic Acids. , 1993 .

[39]  S. Lemaire,et al.  Characterization of [125I][Ser1]histogranin binding sites in rat brain. , 1993, The Journal of pharmacology and experimental therapeutics.

[40]  T. Kato,et al.  Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. , 1993, Journal of medicinal chemistry.

[41]  V. Shukla,et al.  Isolation and characterization of histogranin, a natural peptide with NMDA receptor antagonist activity. , 1993, European journal of pharmacology.

[42]  R. Dubner,et al.  The intrathecal administration of excitatory amino acid receptor antagonists selectively attenuated carrageenan-induced behavioral hyperalgesia in rats. , 1992, European journal of pharmacology.

[43]  K. Franklin,et al.  Dopamine receptor subtypes and formalin test analgesia , 1991, Pharmacology Biochemistry and Behavior.

[44]  I. Lemaire.  Selective differences in macrophage populations and monokine production in resolving pulmonary granuloma and fibrosis. , 1991, The American journal of pathology.

[45]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. , 1990, American journal of hypertension.

[46]  R. H. Walmsley,et al.  Manual of pharmacologic calculations with computer programs , 1982 .

[47]  J. Stewart,et al.  A p-methylbenzhydrylamine resin for improved solid-phase synthesis of peptide amides , 1981, Peptides.

[48]  D. Dubuisson,et al.  The formalin test: A quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats , 1977, Pain.

[49]  E. Kaiser,et al.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.

[50]  W. Clark,et al.  Accurate freehand injection into the lateral brain ventricle of the conscious mouse. , 1968, Journal of applied physiology.

[51]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.

[52]  Fred E. D'Amour,et al.  A METHOD FOR DETERMINING LOSS OF PAIN SENSATION , 1941 .